Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Claims & Support/References for Claims
  4. Fair Balance
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

Fair Balance

Scheduled Pinned Locked Moved Claims & Support/References for Claims
2 Posts 2 Posters 306 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • G Offline
    G Offline
    GMC
    wrote on last edited by
    #1

    Question: It is our understanding that an APS that only contains dosing information (i.e., a standard dose card with no messages of efficacy or safety) would typically require low level fair balance (as per the Guidance on Base Fair Balance Level Selection and Placement in HCP advertising). However, if an APS contains information relating to dose modifications due to safety concerns, would that change the fair balance requirement from low to middle? (even though the dose modifications section is within the DOSAGE AND ADMISTRATION section of the PM). Dosage modifications seems to be inherently a ‘safety’ concern – and we question whether this would prompt a higher level of fair balance.

    Jennifer CarrollJ 1 Reply Last reply
    0
    • G GMC

      Question: It is our understanding that an APS that only contains dosing information (i.e., a standard dose card with no messages of efficacy or safety) would typically require low level fair balance (as per the Guidance on Base Fair Balance Level Selection and Placement in HCP advertising). However, if an APS contains information relating to dose modifications due to safety concerns, would that change the fair balance requirement from low to middle? (even though the dose modifications section is within the DOSAGE AND ADMISTRATION section of the PM). Dosage modifications seems to be inherently a ‘safety’ concern – and we question whether this would prompt a higher level of fair balance.

      Jennifer CarrollJ Offline
      Jennifer CarrollJ Offline
      Jennifer Carroll
      wrote on last edited by
      #2

      Hey @tmcm

      The nature of the dosing modifications and the manner in which they are presented, will impact the level of fair balance. A dosing tool with cautionary dosing modifications may be subject to the lowest level fair balance. If the modifications are positioned as a product benefit it will likely require highest level fair balance.

      1 Reply Last reply
      0
      Reply
      • Reply as topic
      Log in to reply
      • Oldest to Newest
      • Newest to Oldest
      • Most Votes


      • Login

      • Don't have an account? Register

      • Login or register to search.
      • First post
        Last post
      0
      • Categories
      • Recent
      • Tags
      • Popular
      • Users
      • Groups